INOVIO Reports Homologous Boosting Data For COVID-19 Vaccine Candidate - Quick Facts

INOVIO (INO) said a booster (or third) dose of INO-4800, the company's COVID-19 DNA Vaccine Candidate, significantly increased the immune responses that resulted from the second dose. The data from a phase 1 open-label trial of 120 participants showed INO-4800 was well-tolerated as both a two-dose series and as a homologous booster dose in all adults, including participants 65 years of age and older.

"We believe that INO-4800, if approved, will be well suited to support the continued fight against COVID-19 - both as a primary vaccination and as a booster. We look forward to contributing to the international public health knowledge base via our global phase 3 clinical trial," said Joseph Kim, CEO of INOVIO.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Goldman Sachs Group, Inc. (GS) reported that its third quarter net earnings applicable to common shareholders increased 63 percent year-on-year. Net revenues were also significantly higher reflecting significantly higher net revenues in Investment Banking, Global Markets and Consumer & Wealth Management,... Butterball, LLC recalled about 14,107 pounds of ground turkey products for potential contamination with foreign materials, specifically blue plastic material, the U.S. Department of Agriculture's Food Safety and Inspection Service (FSIS) said in a statement. Specialized Bicycle Components, Inc. is recalling about 6,900 units of Tarmac SL7 Bicycles and Framesets for potential risk of fall and injury hazard, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the bicycle's fork steerer tube can crack or break after harsh impact such as hitting a deep pothole or other stress event, posing fall and injury hazards.
Follow RTT